PDE10A and supranuclear palsy, progressive, 1: In a 2017 published clinical study [113], [18F]26 was used for assessment of the PDE10A availability in the striatum of patients with progressive supranuclear palsy (PSP) and PD to possibly differentiate between these two neurodegenerative disorders by PET.